Psilocybe Mushrooms Constituents—Therapeutic Implications
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: 30 September 2025 | Viewed by 59
Special Issue Editors
Interests: scheduled substances for clinical use; Parkinson’s disease; personalized medicine
Special Issues, Collections and Topics in MDPI journals
Interests: scheduled substances for clinical use; cancer; clinical trials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Psilocybin research has significantly developed in the last decade, but has remained in the space of specific mental health conditions. Furthermore, its biological origins have largely been ignored, as it is only a part of the secondary metabolite arsenal produced by the Psilocybe genus.
We invite submissions on the global Psilocybe community with a specific focus on the intersection of Psilocybe constituents and health outcomes. We will consider pre-clinical (in vitro and in vivo) and clinical primary research papers, in addition to well-structured reviews on Psilocybe use in the context of any health condition. While we will consider papers specifically focusing on psilocybin, we also invite papers that describe interactions of other Psilocybe constituents with a health phenotype/outcome.
You may choose our Joint Special Issue in Cells.
Dr. Andrea Bugarcic
Dr. Janet Schloss
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Psilocybe mushrooms
- psilocybin
- pre-clinical research
- neurodegeneration
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
